New radiation approach aims to tame pituitary tumors with fewer side effects

NCT ID NCT06826170

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a new way of delivering radiation for people with non-secreting pituitary adenomas that came back or remained after surgery. Instead of a single high dose, the radiation was given in five smaller daily doses. The goal was to see if this approach could control tumor growth while reducing damage to nearby nerves and the pituitary gland. Twenty-five patients were followed for at least a year with MRI scans, eye tests, and hormone checks.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
hypofractionated stereotactic radiotherapy (radiation therapy given in 5 daily sessions)
What this could lead to
If successful, this approach could offer a safer way to treat residual or recurrent pituitary tumors with fewer side effects on vision and hormone function.
What could go wrong
This is a small, early-phase study with only 25 participants. It may not confirm long-term safety or effectiveness, and some patients may still experience side effects or tumor progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SECRETING PITUITARY ADENOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Istituto Neurologico C Besta

    Milan, Milan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.